DMAC (STOCKS)
DiaMedica Therapeutics Inc. Common Stock
$6.750000
-0.090000 (-1.32%)
Prev close: $6.840000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Rick John Pauls
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $381.30M
- Employees
- 28
- P/E (TTM)
- -9.45
- P/B (TTM)
- 9.62
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.19 | $-0.20 | +0.0140 | +6.86% |
|
Mar 2026 (Q1)
|
$-0.19 | $-0.19 | -0.0013 | -0.69% |
|
Dec 2025 (Q4)
|
$-0.17 | $-0.18 | +0.0136 | +7.41% |
|
Sep 2025 (Q3)
|
$-0.17 | $-0.16 | -0.0068 | -4.17% |
Financial Statements
| Research and Development | $29.28M |
| Operating Income/Loss | -$39.23M |
| Income/Loss From Continuing Operations After Tax | -$37.54M |
| Income/Loss From Continuing Operations Before Tax | -$37.51M |
| Income Tax Expense/Benefit | $30.00K |
| Net Income/Loss | -$37.54M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$37.54M |
| Net Income/Loss Available To Common Stockholders, Basic | -$37.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.72 |
| Basic Average Shares | 105,286,318 |
| Assets | $45.00M |
| Current Assets | $44.32M |
| Cash | $43.50M |
| Other Current Assets | $815.00K |
| Noncurrent Assets | $686.00K |
| Fixed Assets | $133.00K |
| Other Non-current Assets | $553.00K |
| Liabilities | $6.66M |
| Current Liabilities | $6.59M |
| Accounts Payable | $2.81M |
| Wages | $1.21M |
| Other Current Liabilities | $2.58M |
| Noncurrent Liabilities | $69.00K |
| Equity | $38.34M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $38.34M |
| Liabilities And Equity | $45.00M |
| Net Cash Flow From Operating Activities | -$31.51M |
| Net Cash Flow From Operating Activities, Continuing | -$31.51M |
| Net Cash Flow From Investing Activities | -$11.64M |
| Net Cash Flow From Investing Activities, Continuing | -$11.64M |
| Net Cash Flow From Financing Activities | $44.17M |
| Net Cash Flow From Financing Activities, Continuing | $44.17M |
| Net Cash Flow | $1.02M |
| Net Cash Flow, Continuing | $1.02M |
| Comprehensive Income/Loss | -$37.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$37.56M |
| Other Comprehensive Income/Loss | -$27.45M |